Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(9):1492–1494. doi: 10.1038/bjc.1998.245

Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma.

K Krasagakis 1, D Thölke 1, B Farthmann 1, J Eberle 1, U Mansmann 1, C E Orfanos 1
PMCID: PMC2150189  PMID: 9652767

Abstract

Overexpression of transforming growth factor-beta isoforms (TGF-beta1, -beta2, -beta3) has been previously reported in human melanoma cell lines and tumours. The aim of the present study was to evaluate the plasma levels of TGF-beta isoforms in melanoma patients. Significantly elevated levels of TGF-beta1 (4.2 x the controls, P = 0.0094) and of TGF-beta2 (1.5 x the controls, P = 0.012) but not of TGF-beta3 were measured in patients with disseminated but not locoregional melanoma. These results indicate systemic circulation of potentially immunosuppressive peptides of the TGF-beta family in end-stage melanoma patients.

Full text

PDF
1492

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arteaga C. L., Hurd S. D., Winnier A. R., Johnson M. D., Fendly B. M., Forbes J. T. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993 Dec;92(6):2569–2576. doi: 10.1172/JCI116871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ivanovic V., Melman A., Davis-Joseph B., Valcic M., Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med. 1995 Apr;1(4):282–284. doi: 10.1038/nm0495-282. [DOI] [PubMed] [Google Scholar]
  3. Krasagakis K., Garbe C., Schrier P. I., Orfanos C. E. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res. 1994 Nov-Dec;14(6B):2565–2571. [PubMed] [Google Scholar]
  4. Lüscher U., Filgueira L., Juretic A., Zuber M., Lüscher N. J., Heberer M., Spagnoli G. C. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer. 1994 May 15;57(4):612–619. doi: 10.1002/ijc.2910570428. [DOI] [PubMed] [Google Scholar]
  5. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597–641. doi: 10.1146/annurev.cb.06.110190.003121. [DOI] [PubMed] [Google Scholar]
  6. Reed J. A., McNutt N. S., Prieto V. G., Albino A. P. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol. 1994 Jul;145(1):97–104. [PMC free article] [PubMed] [Google Scholar]
  7. Rodeck U., Bossler A., Graeven U., Fox F. E., Nowell P. C., Knabbe C., Kari C. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 1994 Jan 15;54(2):575–581. [PubMed] [Google Scholar]
  8. Torre-Amione G., Beauchamp R. D., Koeppen H., Park B. H., Schreiber H., Moses H. L., Rowley D. A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486–1490. doi: 10.1073/pnas.87.4.1486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., Kiso S., Imai Y., Shimomukai H., Nomura Y., Matsuda Y. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996 Feb;110(2):375–382. doi: 10.1053/gast.1996.v110.pm8566583. [DOI] [PubMed] [Google Scholar]
  10. Van Belle P., Rodeck U., Nuamah I., Halpern A. C., Elder D. E. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol. 1996 Jun;148(6):1887–1894. [PMC free article] [PubMed] [Google Scholar]
  11. Wahl S. M., McCartney-Francis N., Mergenhagen S. E. Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today. 1989 Aug;10(8):258–261. doi: 10.1016/0167-5699(89)90136-9. [DOI] [PubMed] [Google Scholar]
  12. Wojtowicz-Praga S., Verma U. N., Wakefield L., Esteban J. M., Hartmann D., Mazumder A., Verma U. M. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):169–175. doi: 10.1097/00002371-199605000-00001. [DOI] [PubMed] [Google Scholar]
  13. de Martin R., Haendler B., Hofer-Warbinek R., Gaugitsch H., Wrann M., Schlüsener H., Seifert J. M., Bodmer S., Fontana A., Hofer E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 1987 Dec 1;6(12):3673–3677. doi: 10.1002/j.1460-2075.1987.tb02700.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES